HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rilotumumab extends PFS in gastric cancer.

Abstract
Patients with gastric or esophagogastric cancer treated with combination chemotherapy and rilotumumab, an anti-HGF monoclonal antibody, had longer progression-free survival than patients treated with chemotherapy alone, according to results from a phase II clinical trial. The survival benefit was greatest in patients with MET-positive disease; a phase III trial testing the drug combination's effect on this patient population is now under way.
Authors
JournalCancer discovery (Cancer Discov) Vol. 4 Issue 9 Pg. OF1 (Sep 2014) ISSN: 2159-8290 [Electronic] United States
PMID25185191 (Publication Type: Journal Article, Comment)
Copyright©2014 American Association for Cancer Research.
Chemical References
  • Antibodies, Monoclonal
Topics
  • Adenocarcinoma (drug therapy)
  • Antibodies, Monoclonal (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Esophagogastric Junction (pathology)
  • Female
  • Humans
  • Male
  • Stomach Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: